Companies / DXCM vs SOLV
DXCM vs SOLV: Dexcom and Solventum
Dexcom (DXCM) reported $4.7B in revenue against a 17.9% net margin, while Solventum (SOLV) reported $8.3B at a 18.7% net margin, most recently.
| Metric | DXCM | SOLV |
|---|---|---|
| Revenue | $4.7B | $8.3B |
| Net Income | $0.8B | $1.6B |
| Gross Margin | 60.1% | 53.5% |
| Operating Margin | 19.6% | 26.2% |
| EPS (Diluted) | $2.09 | $8.88 |
| Free Cash Flow | $1.1B | $-10.0M |
| Total Debt | $1.3B | $5.0B |
| P/E Ratio | 31.8× | 8.9× |
| P/B Ratio | 9.3× | 2.7× |
| Stock Price | $84.45 | $87.11 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| DXCM Revenue | $2.9B | $3.6B | $4.0B | $4.7B |
| SOLV Revenue | $8.1B | $8.2B | $8.3B | $8.3B |